XNAS
CV
Market cap326mUSD
Oct 08, Last price
6.62USD
1D
1.22%
1Q
10.52%
IPO
50.45%
Name
CapsoVision Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Key people
David Garcia
Principal Financial Officer, Principal Accounting Officer · since 2025
Kevin Lundquist
Chief Financial Officer · since 2024
Douglas Atkinson
Head - Global Sales · since 2016
Keri Jorgenson
Director of Clinical Operations · since 2025
Rebecca Petersen
Director of Clinical Affairs · since 2022
Min-Liang Chen
Director
Eliyahou Harari
Director
Howard Lee
Director
Heidi Chung Sutardja
Director
Pen-Jung Tseng
Director
Kang-Huai Wang
President, Chief Executive Officer, Co-Founder, Director · since 2024
Julia Gouw
Independent Director Nominee · since 2025
Joanne Imperial
Independent Director Nominee · since 2025
Wen-Herng King
Independent Director Nominee · since 2025
Hui Ying Kuo
Independent Director · since 2024
Chen Lung Tsai
Independent Chairman of the Board · since 2014
Legal address
c/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET
Wilmington, DE 19801
US
Wilmington, DE 19801
US
Headquarters
18805 Cox Avenue, Suite 250
Saratoga, CA 95070
US
Saratoga, CA 95070
US
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |